| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.11 | 0.004 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.094 | 0.004 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.004 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.005 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.006 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.14 | 0.006 |